35 results on '"Di Scala, Lilla"'
Search Results
2. Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society Guidelines.
3. Performance of DETECT PAH algorithm according to the hemodynamic definition of pulmonary arterial hypertension (PAH) in the 2022 ESC/ERS guidelines
4. Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study
5. Correction: Jansa et al. Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension. J. Clin. Med. 2022, 11, 6189
6. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study
7. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
8. Real-World Resource Utilization and Productivity Loss Among Patients With Myasthenia Gravis in Sweden: A Nationwide Population-Based Study
9. Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension
10. Some uses of predictive probability of success in clinical drug development
11. Selexipag for the Treatment of Pulmonary Arterial Hypertension
12. P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study
13. Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): A phenotypic comparison
14. Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model
15. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension
16. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
17. Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study
18. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2 ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study
19. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
20. Management of selexipag interruptions in the GRIPHON study
21. Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH)
22. An approach to confirmatory testing of subpopulations in clinical trials
23. A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein.
24. Correlative biomarker analysis of sequential tumor biopsies in a ph I mode of action (MoA) study in neoadjuvant head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with RG7160 (GA201), a novel dual-acting, monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), with cetuximab (C) as reference.
25. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients
26. A Randomized, Double-blind, Placebo-controlled, Multi-center, Two-period Crossover Study To Investigate The Bronchodilatory Effect Of NVA237 50µg Inhaled Once Daily In Patients With COPD
27. P3-026: A novel Bayesian dose-escalation Phase Ib study design investigating combination of the mammalian target of rapamycin (mTOR) inhibitor RAD001 with standard chemotherapy in patients with lung cancer
28. Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia
29. A novel Bayesian dose-escalation Phase Ib study design investigating combination of the mammalian target of rapamycin (mTOR) inhibitor RAD001 with standard chemotherapy in patients with lung cancer.
30. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2 ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study
31. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
32. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
33. P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study.
34. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.
35. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.